Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of dvanced EGFR-mutated NSCLC after Osimertinib

Antonio Passaro, shared a post on X:

“EMA approves amivantamab in combination with chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after Osimertinib (Mariposa2 combo).”

Read further.
Source: Antonio Passaro/X

Antonio Passaro MD PhD, a medical oncologist at the European Institute of Oncology in Milan, specializes in lung cancer research and treatment. he focuses on developing new therapies, including immunotherapy, and identifying reliable biomarkers for non-small cell lung cancer (NSCLC). Dr. Passaro leads lung cancer trials, evaluates therapeutic efficacy and safety. Authoring over 100 peer-reviewed papers, he also holds editorial positions and key roles in societies like ESMO and AIOM.